SignPath Pharma
Business Services · Utah, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
7984 S 1300 E, Sandy, Utah, 84094, Unite...Phone Number
(215) 538-9996Website
www.signpathpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About SignPath Pharma
Signpath Pharma is a clinical-stage company based in Sandy, Utah, specializing in the development of heart-safe drugs through its unique CorreQT platform. The company focuses on mitigating cardiac side effects associated with various medications, particularly in the context of cancer treatment. Their lead product, LipoCurc, is a proprietary liposomal formulation of curcumin that has shown efficacy in clinical trials without cardiac toxicity. Signpath aims to address significant unmet medical needs by creating innovative treatments for patients, particularly those with cancer and other conditions requiring safer drug alternatives.Explore more
SignPath Pharma Org Chart
JP
Vice President, Cardiology, Chief Medical Off...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SignPath Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if SignPath Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
SignPath Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if SignPath Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if SignPath Pharma had a recent Job posting/layoffs
Earning: See what the market has to say on SignPath Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at SignPath Pharma
Product Launch: Get notified when SignPath Pharma launches new products
Funding: Get notified immidiatlly once SignPath Pharma has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to SignPath Pharma
Compare insights from companies similar to SignPath Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SignPath Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SignPath Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SignPath Pharma.
SignPath Pharma Tech Stack
A closer look at the technologies used by SignPath Pharma
See more technologies
SignPath Pharma News & Media
SignPath Pharma Response to SEC Trading Suspension
SALT LAKE CITY--(BUSINESS WIRE)--On March 17, 2020, SignPath Pharma issued a press release stating its intention to pursue a therapeutic treatment for COVID-19 with SignPath’s proprietary patented drug, Lipocurc™. LipoCurc suppresses inflammatory cytokines which can cause cytokine storm. Cytokine storm is believed by many experts to be a significant cause of the lung and organ damage suffered by some COVID-19 patients. SignPath believes that Lipocurc may be a promising potential therapy for treSignPath Pharma to Focus on Coronavirus Disease (COVID-19) by Developing Treatment for Acute Respiratory Distress Syndrome (ARDS)
SALT LAKE CITY--(BUSINESS WIRE)-- #ARDS--SignPath Pharma today confirmed its commitment to developing a treatment for severe viral infections utilizing Lipocurc™, its patented intravenous formulation of liposomal curcumin. SignPath’s Lipocurc™ is an intravenous treatment, proven to be safe in patients, that profoundly suppresses the multiple pro-inflammatory cytokines that cause severe lung damage (ARDS) in patients with COVID-19 infection caused by coronavirus 2 or SARS-CoV-2. Patients with sevSignPath Pharma, Inc. Announces an Out-license Agreement of Its CorreQTTM Technology for Mitigation of QT Prolongation with Rain Therapeutics Inc.
SALT LAKE CITY--(BUSINESS WIRE)-- #QTprolongation--SignPath Pharma, Inc. Announces an Out-license Agreement of Its CorreQT(TM) Technology for Mitigation of QT Prolongation with Rain Therapeutics Inc.Multiple Myeloma-Causing Plasma Cells Show Intense Uptake of Intravenous Liposomal Curcumin as Reported by SignPath Pharma, Inc. in Paper Published in the Cancer Research Journal “Anticancer Research”
SALT LAKE CITY--(BUSINESS WIRE)--#anticancer--SignPath Pharma, Inc. reported in the March issue of Anticancer Research* that its proprietary intravenous liposomal curcumin (LipoCurc™) concentrates very intensely in the malignant plasma cells that cause multiple myeloma. LipoCurc™ infusion, which achieves blood levels of curcumin in humans that are 1000 – 2000 times more than standard oral curcumin, then concentrates in red and white blood cells, which form a reservoir. By far the greatest uptake
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SignPath Pharma
Sign Up For FreeTo access detailed company insights
Signpath Pharma is a clinical-stage company based in Sandy, Utah, specializing in the development of heart-safe drugs through its unique CorreQT platform. The company focuses on mitigating cardiac side effects associated with various medications, particularly in the context of cancer treatment. Their lead product, LipoCurc, is a proprietary liposom... Read More
